Clinical Scorecard: Mass Spec Roundup: From Alzheimer’s to Antarctic Dust

At a Glance

Key Highlights

• S-nitrosylation of STING at cysteine 148 identified as a driver of chronic neuroinflammation in Alzheimer’s disease.
• Blocking S-nitrosylation of STING in a mouse model reduces neuroinflammatory signaling and protects synapses.
• PFAS exposure through nursing in bottlenose dolphins suggests early-life contaminant transfer with potential human health implications.

Guideline-Based Recommendations

Diagnosis

• Detection of elevated S-nitrosylated STING in human Alzheimer’s brain samples and disease-relevant cell models may aid research diagnosis.

Management

• Development of small molecules targeting cysteine 148 on STING to block S-nitrosylation and reduce damaging neuroinflammation is a promising therapeutic approach.

Monitoring & Follow-up

• Monitor neuroinflammatory markers and synaptic integrity in preclinical models when testing STING-targeted interventions.

Risks

• Potential risk of disrupting normal immune function when targeting STING; selective interference strategies are needed.

Patient & Prescribing Data

Alzheimer’s disease models and human brain tissue samples

Genetic modification preventing STING S-nitrosylation reduces inflammation and synaptic degeneration; small molecule inhibitors are under development.

Clinical Best Practices

• Utilize mass spectrometry and redox chemical biology to identify post-translational modifications driving neuroinflammation.
• Consider targeting specific molecular switches such as STING S-nitrosylation to modulate innate immune signaling in neurodegenerative diseases.
• Incorporate multi-technique analytical approaches for comprehensive detection of environmental contaminants like PFAS in biological samples.

Related Resources & Content

• Scripps Research study on STING S-nitrosylation in Alzheimer’s
• PFAS exposure in bottlenose dolphin milk study
• Single-particle mass spectrometry of Antarctic dust